| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD0530 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.0025 | 0.9 |